Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,339 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A good drug made better: the fulvestrant dose-response story.
Robertson JF, Lindemann J, Garnett S, Anderson E, Nicholson RI, Kuter I, Gee JM. Robertson JF, et al. Among authors: anderson e. Clin Breast Cancer. 2014 Dec;14(6):381-9. doi: 10.1016/j.clbc.2014.06.005. Epub 2014 Jun 24. Clin Breast Cancer. 2014. PMID: 25457991 Review.
Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study.
Kuter I, Gee JM, Hegg R, Singer CF, Badwe RA, Lowe ES, Emeribe UA, Anderson E, Sapunar F, Finlay P, Nicholson RI, Bines J, Harbeck N. Kuter I, et al. Among authors: anderson e. Breast Cancer Res Treat. 2012 May;133(1):237-46. doi: 10.1007/s10549-011-1947-7. Breast Cancer Res Treat. 2012. PMID: 22286314 Clinical Trial.
Differences in the transcriptional response to fulvestrant and estrogen deprivation in ER-positive breast cancer.
Patani N, Dunbier AK, Anderson H, Ghazoui Z, Ribas R, Anderson E, Gao Q, A'hern R, Mackay A, Lindemann J, Wellings R, Walker J, Kuter I, Martin LA, Dowsett M. Patani N, et al. Among authors: anderson h, anderson e. Clin Cancer Res. 2014 Aug 1;20(15):3962-73. doi: 10.1158/1078-0432.CCR-13-1378. Epub 2014 Jun 10. Clin Cancer Res. 2014. PMID: 24916694 Free PMC article. Clinical Trial.
Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer.
Cristofanilli M, Valero V, Mangalik A, Royce M, Rabinowitz I, Arena FP, Kroener JF, Curcio E, Watkins C, Bacus S, Cora EM, Anderson E, Magill PJ. Cristofanilli M, et al. Among authors: anderson e. Clin Cancer Res. 2010 Mar 15;16(6):1904-14. doi: 10.1158/1078-0432.CCR-09-2282. Epub 2010 Mar 9. Clin Cancer Res. 2010. PMID: 20215537 Clinical Trial.
4,339 results